300 related articles for article (PubMed ID: 33922026)
21. Biosimilar granulocyte-colony-stimulating factor for mobilization of autologous peripheral blood stem cells in pediatric hematology-oncology patients.
Cesaro S; Tridello G; Prete A; Dallorso S; Cannata E; Massaccesi E; Risso M; De Bortoli M; Caselli D
Transfusion; 2015 Feb; 55(2):246-52. PubMed ID: 25070657
[TBL] [Abstract][Full Text] [Related]
22. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
23. The Real-World Experience of the Biosimilar (Grastofil
Wong G; Wang K; Pasetka M; Zhang L; Lou J; Majeed H; Flores J; Lam E; DeAngelis C
Curr Oncol; 2022 Feb; 29(3):1349-1369. PubMed ID: 35323315
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
[TBL] [Abstract][Full Text] [Related]
26. Patients' outcome after rescue plerixafor administration for autologous stem cell mobilization: a single-center retrospective analysis.
Spoerl S; Peter R; Wäscher D; Götze K; Verbeek M; Peschel C; Krackhardt AM
Transfusion; 2017 Jan; 57(1):115-121. PubMed ID: 27859332
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation.
Martino M; Gori M; Porto G; Pellicano M; Santoro L; Verduci C; Canale FA; Loteta B; Moscato T; Alati C; Ieracitano MC; Cuzzocrea A; Altomonte M; Florenzano MT; Morabito A; Irrera G; Naso V; Pugliese M; Console G; Ferreri A; Imbalzano L; Tripepi G; Pitino A
Ann Hematol; 2023 Jul; 102(7):1915-1925. PubMed ID: 37079070
[TBL] [Abstract][Full Text] [Related]
28. What is the role of biosimilar G-CSF agents in hematopoietic stem cell mobilization at present?
Korkmaz S; Altuntas F
Transfus Apher Sci; 2017 Dec; 56(6):795-799. PubMed ID: 29153313
[TBL] [Abstract][Full Text] [Related]
29. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT; Stenner-Liewen F; Seifert B; Pfrommer S; Petrausch U; Kiessling MK; Schanz U; Nair G; Mischo A; Taverna C; Schmidt A; Bargetzi M; Stupp R; Renner C; Samaras P
J Clin Apher; 2017 Feb; 32(1):21-26. PubMed ID: 27001243
[TBL] [Abstract][Full Text] [Related]
30. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Publicover A; Richardson DS; Davies A; Hill KS; Hurlock C; Hutchins D; Jenner MW; Johnson PW; Lamb J; Launders H; McKeag N; Newman J; Orchard KH
Br J Haematol; 2013 Jul; 162(1):107-11. PubMed ID: 23614650
[TBL] [Abstract][Full Text] [Related]
31. A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
Laszlo D; Marcacci GP; Martino M; Radice D; Rabascio C; Lucchetti B; Magarò A; Caime A; Menna S; Lionetti MT; Bertolini F
Transfus Apher Sci; 2020 Oct; 59(5):102819. PubMed ID: 32499108
[TBL] [Abstract][Full Text] [Related]
32. Engraftment and outcomes following autologous stem cell transplantation in Hodgkin lymphoma patients mobilized with plerixafor.
Yuan S; Palmer JM; Tsai NC; Dagis A; Nademanee A; Wang S
Hematol Oncol; 2017 Sep; 35(3):281-287. PubMed ID: 26928577
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of a conversion from filgrastim to filgrastim-sndz in stem cell transplant patients undergoing mobilization.
Curry LD; Anders B; Dressler EV; Kennedy L
J Oncol Pharm Pract; 2021 Jun; 27(4):871-876. PubMed ID: 32686616
[TBL] [Abstract][Full Text] [Related]
34. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
35. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E
J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178
[TBL] [Abstract][Full Text] [Related]
36. The comparison of effectiveness and safety between different biosimilars of G-CSF in the mobilization of peripheral blood stem cells (PBSCs) for autologous transplantation (autologous peripheral blood stem cell transplantation, auto-PBSCT).
Wicherska-Pawłowska K; Rybka J; Prajs I; Szmigiel K; Tyc J; Frączak E; Biedroń M; Kalicińska E; Szymczak D; Wróbel T
J Clin Apher; 2020 Jan; 35(1):4-8. PubMed ID: 31663634
[TBL] [Abstract][Full Text] [Related]
37. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
38. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
39. Meloxicam with Filgrastim may Reduce Oxidative Stress in Hematopoietic Progenitor Cells during Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Multiple Myeloma.
Patterson AM; Zhang S; Liu L; Li H; Singh P; Liu Y; Farag SS; Pelus LM
Stem Cell Rev Rep; 2021 Dec; 17(6):2124-2138. PubMed ID: 34510361
[TBL] [Abstract][Full Text] [Related]
40. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
